Sophie Jeannin (Summit Clinical Research, USA)

Sophie Jeannin (Summit Clinical Research, USA)

Dr. Jeannin obtained her medical degree in Paris Medical University, France. She completed her internship in cardiovascular prevention a Paris hospital, and as a CRA/ Project manager in pharma clinical development. She has worked in the R&D and Clinical Development field for more than 25 years with specific expertise in NASH & metabolic disease. Throughout her career, Dr. Jeannin has held international project manager positions, consulting positions in clinical development and quality management, for both pharma and biotech. Prior to joining Summit, Dr. Jeannin worked for 8 years as the Chief Medical Officer (CMO) for Genfit and has led the development program of the drug candidate elafibranor in NASH and PBC. She has brought the drug forward from the initial Phase 2b to the current Phase 3 registration trial for NASH. Dr Jeannin has actively participated in the advancement of NASH drug development, as the Working Group Co-Chair for Clinical Trial Endpoints, and Steering Committee Member of the Liver Forum. She has coordinated and participated in multiple regulatory meetings as Sponsor CMO, both in Europe and in the US.